This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Author: Avi Kapoor | July 31, 2025 12:11pm
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Oppenheimer analyst Matthew Biegler initiated coverage on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with an Outperform rating and announced a price target of $7. CytomX Therapeutics shares closed at $2.32 on Wednesday. See how other analysts view this stock.
Oppenheimer analyst Leland Gershell initiated coverage on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with an Outperform rating and announced a price target of $20. Lexeo Therapeutics shares closed at $4.65 on Wednesday. See how other analysts view this stock.
Citigroup initiated coverage on Life360, Inc. (NASDAQ:LIF) with a Buy rating and announced a price target of $90. Life360 shares closed at $76.40 on Wednesday. See how other analysts view this stock.
Considering buying CTMX stock? Here’s what analysts think:
